Phosphorus Attached Indirectly To Amino Nitrogen By Nonionic Bonding Patents (Class 564/15)
-
Publication number: 20090093664Abstract: Methods and compositions to extract radionuclides such as various actinides and lanthanides from organic and/or aqueous solutions by utilizing extractant functionalized carbon nanotubes are disclosed. More particularly, phosphorous-containing (such as phosphine oxides, phosphoric acids or phosphates) organic extractants and other predesigned extractants (such as crown ethers, calncrown derivatives, malonamide and diglycolamide derivatives, polyethylene glycol derivatives, cobalt dicarbollite derivatives, and N-donating heterocyclic ligands) can be covalently and/or non-covalently employed on the surfaces and/or ends (tips) of carbon nanotubes for the purpose of removal radionuclides such as various actinides and lanthanides from organic and/or aqueous solutions. Extractant functionalized carbon nanotubes can be used for extracting radioactive nuclides from nuclear waste or spent nuclear fuel, which are produced and/or reprocessed from the nuclear power generation or other nuclear application.Type: ApplicationFiled: October 8, 2008Publication date: April 9, 2009Applicant: CHEMNANO MATERIALS, LTD.Inventor: Pingshan Wang
-
Patent number: 7511174Abstract: Provided are novel crystalline and amorphous forms of ibandronic acid, methods for their preparation, and pharmaceutical compositions containing them. Also provided are methods for purifying and assaying ibandronic acid in any crystalline form (or amorphous).Type: GrantFiled: September 22, 2006Date of Patent: March 31, 2009Assignee: Teva Pharmaceutical Industries LtdInventors: Thomas Bayer, Ben-Zion Dolitzky, Revital Lifshitz-Liron, Inna Perutski, Michael Pinchasov
-
Publication number: 20090082524Abstract: The invention provides certain novel water-soluble and water-insoluble monomers for ring opening metathesis polymerization and novel polymers, compositions and products, and related methods thereof.Type: ApplicationFiled: September 19, 2008Publication date: March 26, 2009Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Gregory N. Tew, Ahmad Emad-Eldin Madkour, Sterling Fitzgerald Alfred, Paralee Patten King, Semra Colak
-
Publication number: 20090075944Abstract: The present application describes deuterium-enriched ibandronate, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: August 22, 2008Publication date: March 19, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20090076271Abstract: The present invention relates to intermediates of rosuvastatin and processes for the production thereof.Type: ApplicationFiled: April 18, 2008Publication date: March 19, 2009Inventors: Vinod Kumar Kansal, Brijnath P. Chaurasia, Hitesh K. Patel, Vrajlal Gothalia, Hiren Gandhi
-
Publication number: 20090076285Abstract: The invention relates to a process for the treatment of an aqueous mixture comprising a dipolar aprotic compound, comprising: a) an adsorption step, in which the aqueous mixture is brought into contact with a porous adsorbent, whereby the porous adsorbent is chosen such that the dipolar aprotic compound adsorbs to it more readily than water; b) a desorption step, in which the porous adsorbent is brought into contact with a desorbing agent, whereby a recovery solution is formed comprising the desorbing agent and the dipolar aprotic compound.Type: ApplicationFiled: December 20, 2006Publication date: March 19, 2009Inventor: Jochen Stangl
-
Publication number: 20090069598Abstract: Provided are novel crystalline forms of ibandronic acid, physical data, methods for their preparation, and uses therefor. Also provided are methods for purifying and assaying ibandronic acid in any crystalline form.Type: ApplicationFiled: October 15, 2008Publication date: March 12, 2009Inventors: Thomas Bayer, Ben-Zion Dolitzky, Revital Lifshitz-Liron, Inna Perutski, Michael Pinchasov
-
Publication number: 20090036409Abstract: The present invention is directed to a compound of formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof, and methods for treating inflammatory and serine protease mediated disorders.Type: ApplicationFiled: August 20, 2008Publication date: February 5, 2009Inventors: Michael J. Hawkins, Michael N. Greco, Eugene Powell, Lawrence De Garavilla, Bruce E. Maryanoff
-
Publication number: 20090036400Abstract: A pharmaceutical preparation is disclosed for the prevention, treatment and relief from the consequences of alcohol abuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, Alzheimer's disease, Parkinson's disease, toxic kidney diseases, acute kidney failure, toxic side effects on dosage of chemotherapeutics, diabetes mellitus, Wilson's disease, sideroses and/or ischaemic reperfusion damage, arteriosclerosis and as an antidote against environmental toxins and medicament intoxication. The preparation comprises at least one compound of general formula R-A-X, as active ingredient, where R=straight or branched chain C5-C27 alkyl with double and/or triple bonds and which can be substituted, A=—CO—, —COO—, —POx2?—, —NHy—, —O— and/or —S—, x=2, 3 or 4, y=1 or 2 and X?H, polyol, amino acid, alkylamino, C1- to C3-alkylamino, C1- to C3 hydroxyalkyl and/or 1- to C3-carboxylic acid.Type: ApplicationFiled: October 28, 2005Publication date: February 5, 2009Inventors: Thomas Haehner, Dieter Mueller-Enoch
-
Publication number: 20090029948Abstract: Organic compounds are described, which are capable of forming quaternary salts, quaternary salts thereof with a structure having general formula (I) and their use for the control of phytopathogen fungi.Type: ApplicationFiled: December 15, 2006Publication date: January 29, 2009Applicant: ISAGRO S.p.A.Inventors: Lucio Filippini, Marilena Gusmeroli, Silvia Mormile, Luigi Mirenna
-
Publication number: 20090028925Abstract: The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.Type: ApplicationFiled: May 26, 2006Publication date: January 29, 2009Inventors: Mark D. Erion, Hongjian Jiang, Serge H. Boyer
-
Publication number: 20090005346Abstract: The present invention provides 5-azacytosine derivatives with antiviral activity, specifically having viral replication inhibiting properties, more particularly in DNA viruses such as pox-, papilloma- and herpes viruses in humans. The invention also provides pharmaceutical compositions comprising such 5-azacytosine derivatives as active ingredients in combination with pharmaceutically acceptable carriers, which are useful for the treatment of subjects suffering from viral infections.Type: ApplicationFiled: December 8, 2006Publication date: January 1, 2009Applicants: K.U.Leuven Research & Development, Institute of Organic Chemistry and Biochemistry Academy of Sciences of the Czech RepublicInventors: Antonin Holy, Marcela Krecmerova, Alois Piskala, Graciela Andrei, Erik De Clercq, Robert Snoeck, Johan Neyts, Lieve Naesens
-
Publication number: 20080318255Abstract: The present invention relates to a method (assay) for determining the activity of an enzyme selected from the group consisting of a sphingosine kinase and a phosphatase involved in the sphingolipid pathway by use of a labeled sphingosine.Type: ApplicationFiled: September 28, 2004Publication date: December 25, 2008Inventors: Andreas Billich, Peter Ettmayer, Diana Mechtcheriakova, Peter Nussbaumer, Alexander Wlachos
-
Patent number: 7468360Abstract: Disclosed herein is a compound having a structure: Therapeutic methods, compositions, and medicaments relating thereto are also disclosed.Type: GrantFiled: August 8, 2007Date of Patent: December 23, 2008Assignee: Allergan, Inc.Inventors: David W. Old, Danny T. Dinh
-
Patent number: 7462739Abstract: Disclosed are ceramide derivatives represented by the following formula 1 or 2, a method for preparing the same, and a therapeutic agent for treating atopic dermatitis including the ceramide derivatives as active ingredients: wherein, R1 and R2 are each independently straight or branched alkyl groups having 4 to 22 carbon atoms. The therapeutic agent for treating atopic dermatitis including the ceramide derivatives as active ingredients according to the present invention may be useful to treat atopic dermatitis, or treat other skin diseases that are required for improving skin inflammations or suppressing epidermal proliferation, by suppressing or improving inflammatory conditions in the atopic dermatitis in addition to giving immunoregulatory functions, and suppressing or improving skin disorders, for example epidermal proliferation that is generally observed in the atopic dermatitis.Type: GrantFiled: December 26, 2007Date of Patent: December 9, 2008Assignee: Neopharm Co., Ltd.Inventors: Byeong-Deog Park, Jong-Kyung Youm, Hyung-Sub Gwak, Mi-Jung Kwon, Hwan-Mook Kim, Jong-Soon Kang, Sang-Bae Han
-
Publication number: 20080269524Abstract: The invention concerns a method for the isolation of a stereoisomer from a mixture comprising the two stereoisomers of the general formulae (I-A) and (I-A?) and/or the two stereoisomers of the general formulae (I-B) and (I-B?) in which R1, R2 and R3, identical or different, are selected from the group consisting of —H, —F, —Cl, —C1-C6-alkyl, —S—C1-C6-alkyl, —OH, —O—C1-C6-alkyl, —O—C1-C6-alkylenephenyl, —OCO—C1-C6-alkyl, —OCON(C1-C6-alkyl)2 and —O—SiR8R9R10 (in which R8, R9 and R10, identical or different, are —C1-C6-alkyl or -phenyl); R4 is —H or —C1-C6-alkyl; R5 is —C1-C6-alkyl; and R6 and R7, identical or different, are —H or —C1-C6-alkyl; or their salts with organic or inorganic acids; comprising the step (a) manipulating the mixture ratio of the stereoisomers in the mixture so that at least one of the stereoisomers is present in an enantiomeric excess.Type: ApplicationFiled: May 29, 2006Publication date: October 30, 2008Applicant: Gruenenthal GmbHInventors: Helmut Heinrich Buschmann, Wolfgang Hell
-
Publication number: 20080255070Abstract: The disclosure provides, inter alia, novel bisphosphonate compounds and methods of making and using such compounds. In certain embodiments, compounds of the invention include bisphosphonates that are capable of selectively inhibiting one or more of farnesyl diphosphate synthase (FPPS), geranylgeranyl diphosphate synthase (GGPPS), and decaprenyl pyrophosphate synthase (DPPS). In preferred embodiments, compounds of the invention are capable of selectively inhibiting two or more of FPPS, GGPPS, and DPPS. In embodiments, compounds and methods of the invention demonstrate superior activity levels, such as in the anti-cancer context, immunostimulation context, and other contexts, which in several cases exceed the activity levels of previous generation bisphosphonate drugs by orders of magnitude. In embodiments, the invention provides compounds and methods in connection with research and therapeutic applications, e.g.Type: ApplicationFiled: April 11, 2008Publication date: October 16, 2008Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Eric OLDFIELD, Yonghui ZHANG
-
Publication number: 20080255386Abstract: The invention relates to a novel multi step synthesis of 3-(N-methyl-N-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid, monosodium salt, monohydrate, of the formulaType: ApplicationFiled: April 1, 2008Publication date: October 16, 2008Inventor: Bernd Junghans
-
Publication number: 20080249070Abstract: The present invention provides sphingosine-1-phosphate analogs that are potent, and selective agonists at one or more S1P receptors, specifically the S1P1 receptor type. The compounds invention include compounds having a phosphate moiety as well as compounds with hydrolysis-resistant phosphate surrogates such as phosphonates, alpha-substituted phosphonates, and phosphothionates.Type: ApplicationFiled: February 14, 2006Publication date: October 9, 2008Inventors: Kevin R. Lynch, Timothy L. MacDonald
-
Publication number: 20080234405Abstract: A material contains at least a polymerizable N,O-functionalized acrylic acid hydroxyamide of the Formula (I) in which A is an n+m-valent linear or branched aliphatic C1 to C50 radical, in which the carbon chain can be interrupted by O, S, —CO—O—, CO—NH, O—CO—NH or NH—CO—NH, an n+m-valent aromatic C6 to C18 radical or an n+m-valent cycloaliphatic or heterocyclic C3 to C18 radical, wherein the radicals can carry one or more substituents, Y is not present, or is O, S, an ester, amide or urethane group, R1 is hydrogen, an aliphatic C1 to C20 alkyl or C3 to C8 cycloalkyl radical which can carry one or more substituents, R2 is H or a C1 to C10 alkyl radical, R3 is not present or is a C1 to C16 alkylene radical which can be interrupted by O, HG is not present, is —COOH, —P?O(OH)2; —P?O(OH)(OR4); —O—P?O(OH)2, —SO2OH or —O—P?O(OH)(OR4), R4 is a C1 to C15 alkyl radical, phenyl or benzyl radical and n is a number from 1 to 5 and m a number from 0 to 3.Type: ApplicationFiled: September 11, 2007Publication date: September 25, 2008Applicant: Ivoclar Vivadent AGInventors: Norbert Moszner, Iris Lamparth, Urs Karl Fischer, Frank Zeuner, Armin de Meijere, Volker M. Rheinberger
-
Publication number: 20080227683Abstract: Disclosed is the use of compounds of formula (I) wherein X, Y and Z are as defined in the description of the invention, for the preparation of an antitumor medicament, optionally in combination with different biologically active substances.Type: ApplicationFiled: February 8, 2005Publication date: September 18, 2008Applicant: DEFIANTE FARMACEUTICA LDAInventors: Gianfranco Peluso, Menotti Calvani
-
Publication number: 20080221353Abstract: The present invention provides an ionic liquid including a quaternary phosphonium salt represented by general formula (1): wherein R1, R2, R3, and R4 each represent a linear alkyl group having 1 to 6 carbon atoms, a branched alkyl group having 3 to 6 carbon atoms, an alicyclic alkyl group having 3 to 6 carbon atoms, or an alkoxyalkyl group represented by —(CH2)nO—R5 (wherein n is an integer of 1 to 6; and R5 represents a methyl group or an ethyl group); at least one of R1, R2, R3, and R4 is an alkoxyalkyl group; R1, R2, R3, and R4 may be the same or different; R1 and R2 together may form a ring; and X represents an anion. The present invention also provides a reaction solvent including the ionic liquid.Type: ApplicationFiled: March 5, 2008Publication date: September 11, 2008Applicant: Nippon Chemical Industrial Co., Ltd.Inventor: Katsuhiko Tsunashima
-
Publication number: 20080221354Abstract: The present invention relates to a process for the preparation of the alkoxyamine 2-methyl-2-[N-(diethoxy-phosphoryl-2,2-dimethylpropyl)aminoxy]propionic acid or of its salts comprising a stage of saponification of an azo compound in the presence of a base, a stage of photolysis of the salt resulting from the saponification stage in the presence of N-(tert-butyl)-1-diethylphosphono-2,2-dimethylpropyl nitroxide and optionally a stage of acidification of the salt of the alkoxyamine obtained on conclusion of the photolysis stage. The alkoxyamine or its salts can be used as radical polymerization initiators.Type: ApplicationFiled: May 10, 2005Publication date: September 11, 2008Inventors: Jean-Luc Couturier, Didier Gigmes, Olivier Guerret, Yohann Guillaneuf
-
Publication number: 20080214801Abstract: The present invention features a chemoselective ligation reaction that can be carried out under physiological conditions. In general, the invention involves condensation of a specifically engineered phosphine, which can provide for formation of an amide bond between the two reactive partners resulting in a final product comprising a phosphine moiety, or which can be engineered to comprise a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine byproduct and producing a native amide bond in the final product. The selectivity of the reaction and its compatibility with aqueous environments provides for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).Type: ApplicationFiled: October 18, 2007Publication date: September 4, 2008Inventors: Eliana Saxon, Carolyn Ruth Bertozzi
-
Publication number: 20080206151Abstract: The present invention relates to a process for the manufacture of targeting liposomes comprising vector compounds conjugated to the hydrophilic part of modified phospholipids. The present invention provides the modified phospholipids and liposomes containing said modified phospholipids.Type: ApplicationFiled: April 25, 2006Publication date: August 28, 2008Inventor: Alan Cuthbertson
-
Publication number: 20080207913Abstract: The present invention provides bifunctional polymers, methods of preparing the same, and intermediates thereto. These compounds are useful in a variety of applications including the PEGylation of biologically active molecules. The invention also provides methods of using said compounds and compositions thereof.Type: ApplicationFiled: April 27, 2007Publication date: August 28, 2008Applicant: Intezyne TechnologiesInventors: Kurt Breitenkamp, Kevin N. Sill, Habib Skaff
-
Patent number: 7417164Abstract: A novel class of compounds that includes HPTS-Cys-MA, and methods of making them are disclosed herein. The class of compounds including HPTS-Cys-MA are useful as fluorescent dyes for analyte detection.Type: GrantFiled: July 24, 2007Date of Patent: August 26, 2008Assignee: Glumetrics Inc.Inventor: Jeff T. Suri
-
Publication number: 20080199454Abstract: The present invention relates to compounds of formula I which are prodrugs of caspase inhibitors and pharmaceutically acceptable salts thereof. This invention further relates to the release of caspase inhibitors from these compounds through selective bond cleavage. This invention further relates to pharmaceutical compositions comprising these compounds, which are particularly well-suited for treatment of caspase-mediated diseases, including inflammatory and degenerative diseases. This invention further relates to methods for preparing compounds of this invention.Type: ApplicationFiled: December 21, 2007Publication date: August 21, 2008Inventors: Michael Mortimore, Julian M.C. Golec
-
Patent number: 7414151Abstract: The preset invention relates to a cost effective, high yielding, reproducible method for the manufacture of alendronic acid or its salt, such as sodium alendronate, from inexpensive and readily available pyrrolidone using phosphonating agents such as PCl3 in the presence of acids such as sulphonic acids, sulphuric acid or phosphoric acid, and pharmaceutical dosage forms of alendronic acid or pharmaceutically acceptable salts thereof.Type: GrantFiled: December 27, 2006Date of Patent: August 19, 2008Assignee: IPCA Laboratories Ltd.Inventors: Ashok Kumar, Suneel Yeshwant Dike, Avinash Manohar Nijasure, Vijaya Bhaware
-
Publication number: 20080188683Abstract: The invention relates to a stable water soluble composition containing lithophosphatidylethanol amine (LPE) or lecithin including the LPE 3% or more. The composition comprises one or both of lysophosphatidylethanol amine and lecithin 0.1 to 50 wt %, fatty acid or salt thereof 0.1 to 60 wt % and solvent 10 to 99.8 wt %. According to the invention, it is possible to provide the stable water soluble composition of lithophosphatidylethanolamine and lecithin which does not cause the precipitation at the room temperature below 20° C. and can maintain the clear formulation even during the long term keeping.Type: ApplicationFiled: June 30, 2006Publication date: August 7, 2008Applicant: Doosan CorporationInventors: Guk Hoon Chung, Ji Heun Hong, Young Lae Yang
-
Publication number: 20080182824Abstract: The invention provides novel N-benzyl-N-propargyl-amines that are monoamine oxidase inhibitors, but generally exhibit little or no CNS effects.Type: ApplicationFiled: January 25, 2008Publication date: July 31, 2008Applicant: JENRIN DISCOVERYInventors: John F. McElroy, Robert J. Chorvat
-
Publication number: 20080161272Abstract: Disclosed are ceramide derivatives represented by the following formula 1 or 2, a method for preparing the same, and a therapeutic agent for treating atopic dermatitis including the ceramide derivatives as active ingredients: wherein, R1 and R2 are each independently straight or branched alkyl groups having 4 to 22 carbon atoms. The therapeutic agent for treating atopic dermatitis including the ceramide derivatives as active ingredients according to the present invention may be useful to treat atopic dermatitis, or treat other skin diseases that are required for improving skin inflammations or suppressing epidermal proliferation, by suppressing or improving inflammatory conditions in the atopic dermatitis in addition to giving immunoregulatory functions, and suppressing or improving skin disorders, for example epidermal proliferation that is generally observed in the atopic dermatitis.Type: ApplicationFiled: December 26, 2007Publication date: July 3, 2008Inventors: Byeong-Deog Park, Jong-Kyung Youm, Hyung-Sub Gwak, Mi-Jung Kwon, Hwan-Mook Kim, Jong-Soon Kang, Sang-Bae Han
-
Publication number: 20080139845Abstract: A novel form of Ibandronate sodium which is particularly suitable for pharmaceutical applications, and a process for preparing said novel form.Type: ApplicationFiled: December 20, 2007Publication date: June 12, 2008Inventors: David A. Stradiotto, Allan W. Rey, Probal Kanti Datta, Krista Lyn Traynor, Cameron L. McPhail
-
Patent number: 7381745Abstract: The present invention relates to novel compounds and formulations thereof which compounds are ligands, e.g., agonists or antagonists, for a metabotropic glutamate receptor or a NAALADase enzyme or both. The present invention also relates to methods of modulating the activity of a metabotropic glutamate receptor or a NAALADase enzyme or both, e.g., in a subject in need thereof, using a compound or formulation of the present invention. The present invention also relates to methods of treating a subject suffering from a chronic or acute disease, malady or condition due at least in part to an abnormality in the activity of an endogenous metabotropic glutamate receptor or a NAALADase enzyme or both, using a compound or formulation of the present invention.Type: GrantFiled: February 25, 2003Date of Patent: June 3, 2008Assignee: Georgetown UniversityInventors: Alan P. Kozikowski, Jarda T. Wroblewski, Fajun Nan
-
Publication number: 20080125398Abstract: 2-{[2-(Substituted amino)ethyl]sulfonyl}ethyl N,N,N?,N?-tetrakis(2-chloroethyl)-phosphorodiamidates, their preparation and intermediates in their preparation, pharmaceutical compositions containing them, and methods of treatment using them. The compounds are useful for treating cancer, alone and in combination with other anticancer therapies.Type: ApplicationFiled: November 29, 2006Publication date: May 29, 2008Inventors: Wenli Ma, Kevin T. Weber, Robert M. Yee
-
Patent number: 7247731Abstract: One aspect of the present invention relates to novel ligands for transition metals. A second aspect of the present invention relates to the use of catalysts comprising these ligands in transition metal-catalyzed carbon-heteroatom and carbon-carbon bond-forming reactions. The subject methods provide improvements in many features of the transition metal-catalyzed reactions, including the range of suitable substrates, reaction conditions, and efficiency.Type: GrantFiled: September 16, 2005Date of Patent: July 24, 2007Assignee: Massachusetts Institute of TechnologyInventors: Stephen L. Buchwald, David W. Old, John P. Wolfe, Michael Palucki, Ken Kamikawa
-
Patent number: 7169817Abstract: The present invention relates to biphenylyl derivatives, processes for their production, their uses and pharmaceutical compositions containing them. Compounds according to the present invention are based upon the chemical formula: wherein the substituents have the values mentioned herein.Type: GrantFiled: May 27, 2003Date of Patent: January 30, 2007Assignee: IRM LLCInventors: Shifeng Pan, Nathanael S. Gray, Wenqui Gao, Klaus Hinterding, Sophie Lefebvre, Yuan Mi, Peter Nussbaumer, Wei Wang, Federic Zecri, Fan Yi, Lawrence Blas Perez, Kenneth Richad la Montagne, Peter Ettmayer
-
Patent number: 7148382Abstract: Compounds of formula (I), wherein A is S or O; x is 0 or 1; a is SR10 or N(R11)(R12); R1 and R2 are C1–C24alkyl, OR10, CF3 or halogen; R3, R4 and R5 are hydrogen, C1–C24alkyl, OR10 or halogen; or two of the radicals R11 R21 R31 R4 and/or R9 together form C1–C2oalkylene uninterrupted or interrupted by O, S or NR13; R6, R11 R8 and R9 are hydrogen, C1–C24alkyl; C2–C24alkyl which is interrupted one or more times by non-consecutive O atoms and unsubstituted or substituted by OH and/or SH, or R6, R7, R8 and Rg are OR10; halogen; or phenyl unsubstituted or substituted one or more times by C-Calkyl; R10, R11 and R12 are e.g. hydrogen; X is e.g.Type: GrantFiled: August 13, 2002Date of Patent: December 12, 2006Assignee: Ciba Specialty Chemicals CorporationInventors: Jean-Pierre Wolf, Gebhard Hug
-
Patent number: 7148176Abstract: The present invention is directed to phosphine ligands and the use of such ligands in catalytic complexes with transition metals. The catalysts may be used in a variety of reactions and are especially useful for refining halogenoaromatics.Type: GrantFiled: July 27, 2001Date of Patent: December 12, 2006Assignee: Degussa AGInventors: Matthias Beller, Wilhelm Hubert Ehrentraut, legal representative, Theresia Elisabeth Ehrentraut, legal representative, Christa Fuhrmann, Alexander Zapf, Andreas Ehrentraut, deceased
-
Patent number: 7067701Abstract: This invention relates to processes for making phosphorus compounds R2P—X—PR2, R2P-M, R2P-L and R3P, and the novel cation R2P+(L)-X—P+(L)R2, where R represents an optionally substituted hydrocarbyl group, X represents a bridging group, L represents a leaving group and M represents an alkali metal atom. The invention relates further to a process for making a compound R2P-L from a compound R—H via a new process for making the compound R—Li followed by its reaction with a compound Hal2P-L. The compound R2P—X—PR2 is a ligand suitable for making catalysts for copolymerizing carbon monoxide and a olefinically unsaturated compound.Type: GrantFiled: January 15, 2004Date of Patent: June 27, 2006Assignee: SRI InternationalInventors: Roelof Van Ginkel, Alexander Van Der Made, Jan De With, Ursula Eilenberg-Robben, legal representative, Wolf Eilenberg, deceased
-
Patent number: 7064231Abstract: The invention relates to stereoisomerically enriched diamines, to metal complexes comprising these diamines and also to their use in a process for asymmetrically reducing ketones using silanes, in particular polymethylhydrosiloxane, as reducing agents.Type: GrantFiled: August 19, 2003Date of Patent: June 20, 2006Assignee: Bayer AktiengesellschaftInventor: Jürgen Köcher
-
Patent number: 7038083Abstract: Provided is a novel method of making bisphosphonic acids, e.g. risedronic acid, including the step of combining a carboxylic acid, phoshorous acid, and a halophosphorous compound in the presence of a diluent that is an aromatic hydrocarbon or a silicone fluid. When the diluent is an aromatic hydrocarbon, a inert support or ortho-phosphoric acid codiluent is advantageously included.Type: GrantFiled: May 19, 2003Date of Patent: May 2, 2006Assignee: Teva Pharmaceutical Industries, Ltd.Inventors: Rami Lidor-Hadas, Zvi Harel, Revital Lifshitz-Liron, Eti Kovalevski
-
Patent number: 7034015Abstract: The invention relates to a novel class of aminobenzophenones derivatives, to pharmaceutical preparations comprising said compounds, to dosage units of such preparations, to methods of treating patients comprising administering said compounds, and to the use of said compounds in the manufacture of pharmaceutical preparations.Type: GrantFiled: August 28, 2002Date of Patent: April 25, 2006Assignee: Leo Pharma A/SInventors: Erik Rytter Ottosen, Anne Marie Horneman, Xifu Liang
-
Patent number: 7001922Abstract: The invention provides compounds and methods for using them to inhibit the growth of microorganism that expresses Peptide Deformylase, the compounds having the general formula:Type: GrantFiled: November 14, 2003Date of Patent: February 21, 2006Assignee: Celmed Oncology (USA), Inc.Inventors: Carlo Ballatore, Maria V. Sergeeva, Venkata Ramana Doppalapudi
-
Patent number: 6963008Abstract: New hydrate forms of alendronate sodium, having water content of between about one and about twelve percent, and processes for their manufacture, are disclosed. New crystalline forms of alendronate sodium B, D, E, F, G and H, and processes for manufacturing them, are also disclosed. These new forms of alendronate sodium are suitable for incorporation into pharmaceutical compositions for combating bone resorption in bone diseases.Type: GrantFiled: December 31, 2003Date of Patent: November 8, 2005Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Nina Finkelstein, Ramy Lidor-Hadas, Judith Aronhime
-
Patent number: 6924389Abstract: Diphosphine of formula I R1R2P—H2C—Ar—CH2PR1R2??(I) are prepared by a process that comprises a) reacting a dimethyl compound of formula II H3C—Ar—CH3??(II) with a base and an N-substituted aminophosphorous halide to form bis(aminophosphinomethyl) compound of the formula III R3R4P—H2C—Ar—CH2—PR3R4??(III) b) reacting the compound of formula III with HCl to form bis(dichlorophosphinomethyl) compound of formula IV Cl2P—H2C—Ar—CH2—PCl2??(IV) and c) reacting the compound of formula IV with an organometallic reagent to give the product compound of formula I, wherein groups R1 and R2 are each, independently of one another, a substituted or unsubstituted aromatic, heteroaromatic or aliphatic hydrocarbon group and may have a covalent bond connecting them and Ar is a substituted or unsubstituted aromatic or heteroaromatic hydrocarbon group an R3 and R4 are each, independently of one another, an N-substituted alkylamino or arylamino group.Type: GrantFiled: March 19, 2002Date of Patent: August 2, 2005Assignee: Oxeno Olefinchemie GmbHInventors: Ralf Jackstell, Holger Klein, Matthias Beller, Klaus-Diether Wiese, Cornelia Borgmann
-
Patent number: 6906212Abstract: Disclosed are novel phosphine-phosphoramidite compounds which may be employed in combination with a catalytically-active metal to effect a wide variety of reactions such as asymmetric hydrogenations, asymmetric reductions, asymmetric hydroborations, asymmetric olefin isomerizations, asymmetric hydrosilations, asymmetric allylations, asymmetric conjugate additions, and asymmetric organometallic additions. Also disclosed are a process for the preparation of the phosphine-phosphoramidite compounds, metal complex compounds comprising at least one of the phosphine-phosphoramidite compounds and a catalytically-active metal and hydrogenation processes utilizing the metal complex compounds.Type: GrantFiled: June 25, 2004Date of Patent: June 14, 2005Assignee: Eastman Chemical CompanyInventor: Neil Warren Boaz
-
Patent number: 6855849Abstract: Non-C2-symmetric bisphospholane ligands and methods for their preparation are described. Use of metal/non-C2-symmetric bisphospholane complexes to catalyze asymmetric transformation reactions to provide high enantiomeric excesses of formed compounds is also described.Type: GrantFiled: September 18, 2002Date of Patent: February 15, 2005Assignee: Warner-Lambert CompanyInventors: Garrett Stewart Hoge, II, Om Prakash Goel
-
Publication number: 20040266737Abstract: The present invention provides pharmaceutical preparations and the uses thereof for preventing and/or treating seizures and other electroconvulsive disorders by administering a pharmaceutically effective amount of a therapeutic compound having the following formula (I): 1Type: ApplicationFiled: May 14, 2004Publication date: December 30, 2004Applicant: University of KentuckyInventors: Peter A. Crooks, Aimee Karis Bence, David Robert Worthern
-
Publication number: 20040204613Abstract: Compounds of formula (I), wherein A is S or O; x is 0 or 1; a is SR10 or N(R11)(R12); R1 and R2 are C1-C24alkyl, OR10, CF3 or halogen; R3, R4 and R5 are hydrogen, C1-C24alkyl, OR10 or halogen; or two of the radicals R11 R21 R31 R4 and/or R9 together form C1-C2oalkylene uninterrupted or interrupted by O, S or NR13; R6, R11 R8 and R9 are hydrogen, C1-C24alkyl; C2-C24alkyl which is interrupted one or more times by non-consecutive O atoms and unsubstituted or substituted by OH and/or SH, or R6, R7, R8 and Rg are OR10; halogen; or phenyl unsubstituted or substituted one or more times by C-Calkyl; R10, R11 and R12 are e.g. hydrogen; X is e.g. (II), and R2; have one of the meanings given for R1 and R2; and R3′, R4′ and Rs′ have one of the meanings given for R3, R4 and R5; are suitable as photoinitiators, especially for irradiation with light of relatively long wavelengths.Type: ApplicationFiled: February 4, 2004Publication date: October 14, 2004Inventors: Jean-Pierre Wolf, Gebhard Hug